TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update

Go back to TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update

Form 6-K NOVO NORDISK A S For: Sep 20

September 20, 2024 9:48 AM EDT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

... More